MISSISSAUGA, Ontario--(BUSINESS WIRE)--Therapure Biopharma Inc. announces that it is the recipient of the Mississauga Board of Trade’s (MBOT’s) 2017 Business Awards of Excellence. Hundreds of members and honoured guests were on hand for this sold out event, held at the Mississauga Convention Centre on Thursday, November 16, 2017.
In winning the MBOT award, Therapure demonstrated:
- Growth and success in commercializing technological innovations by focusing on the manufacture of complex biologics for its clients and the development, scale up and manufacture of its own blood and plasma-related therapeutic products.
- Adaptability and successful application of new technology using a proprietary protein separation technology called PlasmaCap EBA™. This technology is utilized to produce IVIG, among other products, and our IVIG product candidate has advanced to phase III clinical studies.
- Development and growth as evidenced by a compound annual growth rate of approximately 50% since 2010 that attests to its successful business model, the increasing demand for its products and services and continued client satisfaction.
“Every year, the Mississauga Board of Trade accepts nominations to honour outstanding businesses in ten different categories. This year we received a record number of nominations and we were thrilled that Therapure Biopharma was one such company. When you consider the thousands of businesses in Mississauga, it is quite an accomplishment to be nominated for an Award of Excellence. Congratulations to Therapure Biopharma contributing to a successful business community in Mississauga,” says David Wojcik, President & CEO, Mississauga Board of Trade.
“Therapure is honoured to receive this award within our community amongst outstanding companies and entrepreneurs,” says Nick Green, Therapure’s President and CEO. “And we thank MBOT for recognizing our talented and dedicated people who are passionate about making a difference and having a positive impact on people’s lives.”
Therapure Biomanufacturing’s capabilities and expertise include cell line development, upstream and downstream process development, cGMP manufacturing for preclinical, clinical and commercial drug supply and aseptic fill/finish of injectable drugs. These integrated services allow Therapure to compete successfully in the global biomanufacturing sector.
About Therapure Biopharma Inc.
Therapure is a biopharmaceutical company focused on manufacturing complex biologics for its clients and on developing, manufacturing and selling its own blood and plasma-related therapeutic products. Its passion for quality and patient safety underpins everything it does in its three divisions: Therapure Biomanufacturing, an award-winning contract development and manufacturing division; Therapure Biologics, a division focused on using its proprietary PlasmaCap EBA™ technology to develop a portfolio of plasma-derived pharmaceutical products; and Therapure Innovations, a proprietary therapeutics and platform technologies research and development division. Therapure operates out of two facilities located in Mississauga: a 136,000 sq. ft. cGMP facility that includes biomanufacturing, research and quality control laboratories and is built to meet FDA (US), HPFB (Canada), EMA (Europe) and MHRA (UK) standards, and a new 44,000 sq. ft. facility housing 30,000 sq. ft. of cGMP warehouse.
Visit www.therapurebio.com for more information about Therapure Biopharma Inc. and its divisions.
About MBOT’s Business Awards of Excellence
The Mississauga Board of Trade hosted its 2017 Business Awards of Excellence ceremony on Thursday, November 16, 2017 at the Mississauga Convention Centre. Since 1980, the Mississauga Board of Trade has been recognizing Mississauga businesses and professionals whose business achievements or community involvement have made significant contributions to the economic and social well-being of the City of Mississauga. This annual event brings together businesses, government and industry leaders for a night of celebration and prestige.